Company intelligence / Profile preview
AIGEN Sciences
Seoul, Seoul Special City, South Koreaaigensciences.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
AIGEN Sciences has developed an award-winning AI drug discovery platform that enables the direct identification of high-potency drugs with minimal off-target effects and toxicity. The company is advancing a pipeline focused on cancer and rare diseases, supported by recent Series A funding. No clinical results have been published yet.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on AIGEN Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIGEN Sciences.